Crossmark

A multicenter analysis of trends in resistance in urinary Enterobacterales isolates from ambulatory patients in the United States: 2011–2020

Published Online: 2022-02-28

Published Print: 2022-12

Authors

Dunne, Michael W.

Aronin, Steven I.

Yu, Kalvin C.

Watts, Janet A.

Gupta, Vikas
Funding

Funding for this research was provided by:

Iterum Therapeutics
License Information

Text and Data Mining valid from 2022-02-28

Version of Record valid from 2022-02-28
More Information

Article History

Received: 8 December 2021

Accepted: 14 February 2022

First Online: 28 February 2022

Declarations

:

: The study was performed in accordance with all relevant guidelines and regulations, including the Declaration of Helsinki. Ethical approval for this study was received from the New England Institutional Review Board (Wellesley, Massachusetts; No. 120180023). Outcome studies using this retrospective, deidentified dataset were approved and informed consent was waived by the New England Institutional Review Board (Wellesley, Massachusetts; No. 120180023).

: Not applicable.

: MWD and SIA are employees of and own stock in Iterum Therapeutics. KCY, JW, and VG are employees of Becton, Dickinson & Company, which was contracted by Iterum Therapeutics to conduct the study. KCY and VG also own stock in Becton, Dickinson & Company.

Document is current